GRAIL is trading 4.3% down at $134.51 on October 12; the specific reason for the decline remains unclear. - No reliable report identified a new company-specific announcement explaining the drop. - Recent coverage focused on investors weighing the FDA panel’s favorable recommendation for Galleri against unresolved questions; final FDA approval is still pending. That earlier news does not establish today’s cause. - The broader market was mixed and does not clearly explain the decline.